1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Community Acquired Pneumonia - Pipeline Review, H1 2016

Community Acquired Pneumonia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 110 pages

Community Acquired Pneumonia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Community Acquired Pneumonia - Pipeline Review, H1 2016’, provides an overview of the Community Acquired Pneumonia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Community Acquired Pneumonia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
- The report reviews pipeline therapeutics for Community Acquired Pneumonia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Community Acquired Pneumonia therapeutics and enlists all their major and minor projects
- The report assesses Community Acquired Pneumonia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Community Acquired Pneumonia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Community Acquired Pneumonia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Community Acquired Pneumonia Overview 8
Therapeutics Development 9
Pipeline Products for Community Acquired Pneumonia - Overview 9
Community Acquired Pneumonia - Therapeutics under Development by Companies 10
Community Acquired Pneumonia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Community Acquired Pneumonia - Products under Development by Companies 14
Community Acquired Pneumonia - Companies Involved in Therapeutics Development 15
AstraZeneca Plc 15
BioAegis Therapeutics, Inc. 16
Biotest AG 17
C10 Pharma AS 18
ioGenetics, Inc. 19
Kyorin Pharmaceutical Co., Ltd. 20
Melinta Therapeutics, Inc 21
Merck and Co., Inc. 22
Nabriva Therapeutics AG 23
Paratek Pharmaceuticals, Inc. 24
TaiGen Biotechnology Co., Ltd. 25
Takeda Pharmaceutical Company Limited 26
Tetraphase Pharmaceuticals Inc. 27
Community Acquired Pneumonia - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
BT-086 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
C-10 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
ceftaroline fosamil - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
DBAF-301 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
delafloxacin - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
KRPAM-1977X - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
lefamulin acetate - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
nemonoxacin - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
omadacycline tosylate - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
PneumoMab - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
radezolid - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Recombinat Protein to Replace Plasma Gelsolin for Community Acquired Pneumonia - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
solithromycin - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
ticagrelor - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
TP-271 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
TP-834 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Community Acquired Pneumonia - Recent Pipeline Updates 71
Community Acquired Pneumonia - Dormant Projects 98
Community Acquired Pneumonia - Discontinued Products 99
Community Acquired Pneumonia - Product Development Milestones 100
Featured News and Press Releases 100
Feb 05, 2016: The Lancet Infectious Diseases Publishes Positive Phase 3 Study Results for Cempra Oral Solithromycin in Community-Acquired Bacterial Pneumonia 100
Feb 01, 2016: Cempra and Macrolide Pharmaceuticals Enter Synthetic Manufacturing Process Development Agreement for Solithromycin 100
Jan 06, 2016: Melinta Therapeutics Initiates Phase 3 Study of Baxdela in Hospital-Treated Community-Acquired Bacterial Pneumonia 101
Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents 102
Dec 03, 2015: TaiGen's Intravenous Taigexyn Successfully Achieved Primary Endpoint in Phase 3 Clinical Trial for Community Acquired Pneumonia 103
Nov 09, 2015: Paratek Initiates Omadacycline Phase 3 Clinical Study in Community Acquired Bacterial Pneumonia 103
Nov 04, 2015: Paratek Receives FDA Fast Track Designation for Omadacycline 103
Oct 23, 2015: Cempra to Present Solithromycin Oral Data at CHEST 2015 104
Oct 16, 2015: Cempra Announces Positive Topline Phase 3 Clinical Results for Intravenous Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia 105
Oct 13, 2015: Nabriva Presents Data on Lefamulin at the 2015 ID Week in San Diego 107
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110

List of Tables
Number of Products under Development for Community Acquired Pneumonia, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Community Acquired Pneumonia - Pipeline by AstraZeneca Plc, H1 2016 15
Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics, Inc., H1 2016 16
Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2016 17
Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H1 2016 18
Community Acquired Pneumonia - Pipeline by ioGenetics, Inc., H1 2016 19
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2016 20
Community Acquired Pneumonia - Pipeline by Melinta Therapeutics, Inc, H1 2016 21
Community Acquired Pneumonia - Pipeline by Merck and Co., Inc., H1 2016 22
Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG, H1 2016 23
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H1 2016 24
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 25
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 26
Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 27
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Stage and Target, H1 2016 30
Number of Products by Stage and Mechanism of Action, H1 2016 32
Number of Products by Stage and Route of Administration, H1 2016 34
Number of Products by Stage and Molecule Type, H1 2016 36
Community Acquired Pneumonia Therapeutics - Recent Pipeline Updates, H1 2016 71
Community Acquired Pneumonia - Dormant Projects, H1 2016 98
Community Acquired Pneumonia - Discontinued Products, H1 2016 99

List of Figures
Number of Products under Development for Community Acquired Pneumonia, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 28
Number of Products by Targets, H1 2016 29
Number of Products by Stage and Targets, H1 2016 29
Number of Products by Mechanism of Actions, H1 2016 31
Number of Products by Stage and Mechanism of Actions, H1 2016 31
Number of Products by Routes of Administration, H1 2016 33
Number of Products by Stage and Routes of Administration, H1 2016 33
Number of Products by Molecule Types, H1 2016 35
Number of Products by Stage and Molecule Types, H1 2016 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cell Division Protein FtsZ (ftsz) - Pipeline Review, H2 2016’, provides in depth analysis on Cell Division ...

Bacterial Conjunctivitis - Pipeline Review, H2 2016

Bacterial Conjunctivitis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Bacterial Conjunctivitis - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2016, provides ...

Traveler’s Diarrhea - Pipeline Review, H2 2016

Traveler’s Diarrhea - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Traveler’s Diarrhea - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Traveler’s Diarrhea - Pipeline Review, H2 2016’, provides an overview of the Traveler’s Diarrhea pipeline landscape. ...

Q Fever - Pipeline Review, H2 2016

November 2016 $ 2000

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.